US Broker Ratings

SI-BONE, Inc. (SIBN) Stock Analysis: A Robust 27.85% Potential Upside Beckons Investors

SI-BONE, Inc. (NASDAQ: SIBN) is making waves in the healthcare sector, specifically within the medical devices industry, with a strong focus on innovative solutions for musculoskeletal disorders. This Santa Clara-based..

Arcus Biosciences, Inc. (RCUS) Stock Analysis: Unveiling a 45.98% Upside Potential Amidst Clinical Innovations

Arcus Biosciences, Inc. (NASDAQ: RCUS), a trailblazer in the biotechnology sector, holds a promising position in the healthcare industry with a market capitalization of $2.72 billion. This clinical-stage biopharmaceutical company,..

RxSight, Inc. (RXST) Stock Analysis: Navigating a -16.06% Potential Downside with Innovative Technology

RxSight, Inc. (NASDAQ: RXST), a prominent player in the healthcare sector, specifically within the medical devices industry, is attracting attention due to its innovative approach to cataract surgery. The company’s..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Strong Revenue Growth and Promising Analyst Ratings

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) has been making waves in the healthcare sector, particularly within the drug manufacturing industry specializing in both specialty and generic formulations. With a robust market..

uniQure N.V. (QURE) Stock Analysis: Unveiling a 131% Potential Upside in the Biotech Sector

In the dynamic landscape of biotechnology, uniQure N.V. (NASDAQ: QURE) stands out with an impressive potential upside of 131.20%, making it an intriguing prospect for investors with an eye on..

Immunome, Inc. (IMNM) Stock Analysis: Unveiling a 71.68% Upside Potential in the Fast-Paced Biotech Sector

Immunome, Inc. (NASDAQ: IMNM) is capturing the attention of investors with its promising position in the biotechnology industry. Specializing in the development of targeted cancer therapies, Immunome is currently a..

Maravai LifeSciences Holdings (MRVI) Stock Analysis: An 11.61% Upside in the Biotech Sector

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) has caught the attention of investors with its significant 11.61% potential upside, as reflected by the average analyst price target of $3.93. In the..

CeriBell, Inc. (CBLL) Stock Analysis: 31.82% Upside Potential and Strong Buy Ratings

CeriBell, Inc. (NASDAQ: CBLL), a medical technology company at the forefront of neurological patient care, is turning heads in the healthcare sector. With its innovative approach to diagnosing and managing..

Spyre Therapeutics (SYRE) Stock Analysis: Uncovering a 62.49% Potential Upside in Biotechnology

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, has been capturing investor attention with its ambitious pipeline targeting inflammatory bowel disease (IBD). With a market..

AnaptysBio, Inc. (ANAB) Investor Outlook: Exploring a 36.95% Potential Upside in the Biotech Sector

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company based in San Diego, is making waves in the healthcare sector. With a robust focus on immunology therapeutics, AnaptysBio presents a compelling..

Taysha Gene Therapies (TSHA) Stock Analysis: Biotech Innovator with 97.90% Upside Potential

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is positioned at the frontier of the biotechnology sector, offering investors a compelling opportunity in the realm of gene therapies for central nervous system..

Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Exploring a 152.61% Potential Upside in Gene Editing Revolution

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is making waves in the biotech sector with its groundbreaking focus on genome editing treatments, positioning itself as a critical player in the evolving landscape..

Neuropace, Inc. (NPCE) Stock Analysis: Unveiling a 22.3% Potential Upside in the Medical Device Sector

For investors seeking opportunities within the healthcare sector, particularly in the realm of medical devices, Neuropace, Inc. (NASDAQ: NPCE) presents an intriguing prospect. With a focus on treating drug-resistant focal..

Evolus, Inc. (EOLS) Stock Analysis: Aiming High with Over 150% Potential Upside

Evolus, Inc. (NASDAQ: EOLS) is capturing the attention of investors with its significant growth potential, evidenced by a staggering 157.66% potential upside. As a key player in the healthcare sector,..

Niagen Bioscience, Inc. (NAGE) Stock Analysis: A Biotech Gem with 143% Potential Upside

Niagen Bioscience, Inc. (NAGE), a prominent player in the biotechnology industry, has captured the attention of investors with its remarkable potential upside of 143.08%. Operating within the healthcare sector, Niagen..

Zymeworks Inc. (ZYME) Stock Analysis: A Promising Biotech Play with a 34.62% Upside Potential

For investors eager to capitalize on the burgeoning biotechnology sector, Zymeworks Inc. (NASDAQ: ZYME) presents an intriguing opportunity. With a market capitalization of $2 billion, this clinical-stage biotech company is..

OrthoPediatrics Corp. (KIDS) Investor Outlook: Analysts Forecast 37% Upside Potential

OrthoPediatrics Corp. (NASDAQ: KIDS), a leader in the pediatric orthopedic medical devices sector, presents a compelling opportunity for investors seeking exposure to the healthcare industry. With a focus on designing..

Dianthus Therapeutics, Inc. (DNTH): Investor Outlook on a Biotech with 51% Upside Potential

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a pioneering entity in the biotechnology sector, has been capturing investor attention with its ambitious approach to treating severe autoimmune and inflammatory diseases. A closer..

CureVac N.V. (CVAC) Investor Outlook: Assessing a 26.20% Potential Upside in the Innovative mRNA Space

CureVac N.V. (NASDAQ: CVAC), a prominent player in the biotechnology sector, presents a compelling case for investors intrigued by the transformative potential of messenger RNA (mRNA) technologies. Headquartered in Tübingen,..

Akso Health Group (AHG) Stock Analysis: Unpacking the 415.8% Revenue Growth in China’s Booming Healthcare Sector

Akso Health Group (AHG), a prominent player in China’s medical distribution industry, is capturing headlines with its remarkable 415.8% revenue growth. As a healthcare company operating a multifaceted e-commerce platform,..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds